Evidence map›Paper›PMID 26444028›Full record

ArticleKidney international2016

Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis.

Yanli Yan, Li Ma, Xiaoxu Zhou, Murugavel Ponnusamy, Jinhua Tang, Michelle A Zhuang, Evelyn Tolbert, Georgia Bayliss, Jianwen Bai, Shougang Zhuang

RetractedOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Macrophage Actin Cytoskeleton in Chronic Rejection.Results and problems in cell differentiation · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Targeting Macrophages: Therapeutic Approaches in Diabetic Kidney Disease.International journal of molecular sciences · 2024
    Review
  18. Review
  19. Logic-based mechanistic machine learning on high-content images reveals how drugs differentially regulate cardiac fibroblasts.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  20. Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Yanli YanDepartment of Emergency Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China; Department of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, USA.
Li MaDepartment of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, USA.
Xiaoxu ZhouDepartment of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, USA; Departments of Cardiology, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China.
Murugavel PonnusamyDepartment of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, USA.
Jinhua TangDepartment of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, USA; Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Michelle A ZhuangDepartment of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, USA.
Evelyn TolbertDepartment of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, USA.
Georgia BaylissDepartment of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, USA.
Jianwen BaiDepartment of Emergency Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Shougang ZhuangDepartment of Medicine, Rhode Island Hospital and Alpert Medical School, Brown University, Providence, RI, USA; Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address: szhuang@lifespan.org.
Rhode Island Hospital · USBrown University · USShanghai East Hospital · CN

Funding

Histone deacetylases as novel therapeutic targets for kidney fibrosisR01DK085065 · NIDDK · RHODE ISLAND HOSPITAL · PI ZHUANG, SHOUGANG · 2010 to 2017
$2.8M
NIDDK NIH HHS 5R01DK085065NIDDK NIH HHS R01 DK085065
6 · The paper itself

Abstract

Increased Src activity has been associated with the pathogenesis of renal tumors and some glomerular diseases, but its role in renal interstitial fibrosis remains elusive. To evaluate this, cultured renal interstitial fibroblasts (NRK-49F) were treated with PP1, a selective inhibitor of Src. This resulted in decreased expression of α-smooth muscle actin, fibronectin, and collagen I in response to serum, angiotension II, or transforming growth factor-β1 (TGF-β1). Silencing Src with siRNA also inhibited expression of those proteins. Furthermore, inhibition of Src activity blocked renal fibroblast proliferation. In a murine model of renal interstitial fibrosis induced by unilateral ureteral obstruction, the active form of Src (phopsho-Src Tyr416) was upregulated in both renal interstitial fibroblasts and renal tubular cells of the fibrotic kidney. Its inactivation reduced renal fibroblast activation and attenuated extracellular matrix protein deposition. Src inhibition also suppressed activation of TGF-β1 signaling, activation of the epidermal growth factor receptor and STAT3, and reduced the number of renal epithelial cells arrested at the G2/M phase of the cell cycle after ureteral obstruction. Thus, Src is an important mediator of renal interstitial fibroblast activation and renal fibrosis, and we suggest that Src is a potential therapeutic target for treatment of chronic renal fibrosis.

Indexed as

ActinsAnimalsCell LineCell ProliferationCell SurvivalCollagen Type IEpithelial CellsErbB ReceptorsExtracellular Matrix ProteinsFibrosisG2 Phase Cell Cycle CheckpointsGene SilencingKidneyKidney Tubules, ProximalMaleMice4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidineActinsalpha-smooth muscle actin, mouseCollagen Type IErbB ReceptorsExtracellular Matrix ProteinsProtein Kinase InhibitorsPyrazolesPyrimidinesRNA, Small Interferingsrc-Family KinasesSTAT3 Transcription FactorTransforming Growth Factor beta1epidermal growth factor receptorrenal fibrogenesisrenal interstitial fibroblastsSrctransforming growth factor-β1α-smooth muscle actin

Identifiers

PMID26444028
PMCPMC4824676
OpenAlexW2202217605

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.